New asthma drug TR4 enters first human tests
NCT ID NCT07272135
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called TR4 in 12 adults with mild-to-moderate asthma. TR4 is a beta-2 blocker, which works differently than typical asthma treatments. The main goal was to see if it is safe and tolerable, and to measure its effects on lung function and airway inflammation. Participants received either TR4 or a placebo, and researchers monitored their breathing and other health markers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TR4 (a beta-2 blocker drug)
- What this could lead to
- If it works, this could point toward a new way to control asthma by blocking certain receptors in the airways.
- What could go wrong
- This is a very early Phase 1 trial with only 12 people, so results may not apply to everyone. The drug may not improve asthma or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hammersmith Medicines Research
London, London, NW10 7EW, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can tracking severe asthma over time unlock better treatments?
- Can pressurized breathing boost mucus clearance in lung disease?
- Can a simple breathing test unlock the secrets of chronic cough?
- Can a Breath-Activated inhaler match the standard for asthma control?
- Can a School-Home program tame childhood asthma?
- Could everyday supplements shield your lungs?